Selective carbonic anhydrase IX inhibitors based on coumarin scaffold as promising antimetastatic agents:...

Area of Science:

• Biochemistry
• Oncology
• Medicinal Chemistry

Background:

• Human carbonic anhydrase (hCA) IX is implicated in tumor progression, regulating extracellular pH and cell adhesion.
• hCA IX is a validated target for anti-cancer drug development, particularly for hypoxic tumors.
• Current hCA IX inhibitors are primarily sulfonamide-based, necessitating exploration of alternative chemical scaffolds.

Purpose of the Study:

• To investigate coumarin derivatives as potent and selective inhibitors of human carbonic anhydrase IX (hCA IX).
• To evaluate the anti-tumor and anti-metastatic efficacy of coumarin-based hCA IX inhibitors in preclinical cancer models.

Main Methods:

• In vitro enzymatic assays to determine inhibitory potency and selectivity of coumarin derivatives against hCA IX.
• In vivo studies using mice with CA IX-positive 4T1 mammary tumors to assess therapeutic effects.
• Evaluation of tumor growth and spontaneous/experimental metastasis formation following treatment with coumarin-based inhibitors.

Main Results:

• Coumarin derivatives demonstrated potent and selective inhibition of hCA IX in vitro, distinct from sulfonamide mechanisms.
• Treatment with coumarin-based hCA IX inhibitors led to a significant reduction in tumor growth in vivo.
• These inhibitors also markedly decreased both spontaneous and experimental metastasis in preclinical models.

Conclusions:

• Coumarin-based compounds represent a novel class of selective hCA IX inhibitors with a unique mechanism of action.
• These findings support the therapeutic potential of coumarin derivatives for treating hypoxic cancers by targeting hCA IX.
• The demonstrated anti-tumor and anti-metastatic activities warrant further investigation for clinical translation.